Abstract
The diagnosis and management of heart failure is one of modern medicine’s success stories. As both cardiac imaging and treatment modalities have evolved, the prognosis for managing structurally diseased hearts has improved dramatically [1]. Firmly ensconced in this process are ACE inhibitors, ARBs, Beta blockers, ARNIs, MRAs and CRT [2]. With the advent of the SGLT2 trials heralding CV benefit beginning with EMPA-REG OUTCOME in 2015 [3] and culminating most recently in the publication of the DELIVER trial in 2022[4,5], a new concept in HF treatment has also been established. Now part of guideline directed management of all forms of symptomatic heart failure with and without DM2, SGLT2i therapy has gained wide acceptance
Citation
Duffee D (2023) SGLT2 Inhibitors; Not If but When. SM J Cardiol Cardiovasc 7: 2.